Now, nivolumab -- in combination with chemotherapy -- is indicated for the first-line treatment of adults with unresectable ...

Atezolizumab may improve upon perioperative treatment with trastuzumab and chemotherapy in HER2+, locally advanced, resectable gastric or GEJ cancer, researchers say.

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

For the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

Positive new data suggests that more people facing advanced breast cancer may be able to put off treatment with harsh ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

The drugmaker evaluated a post-surgery Herceptin, Perjeta and chemotherapy regimen over ten years in its phase 3 APHINITY study of 4,804 patients. The regimen slashed the risk of death by 17% ...

The FDA granted standard approval to pembrolizumab (Keytruda) plus trastuzumab (Herceptin) and chemotherapy for the treatment of patients with HER2-positive locally advanced unresectable or metastatic ...

Trastuzumab deruxtecan demonstrated a higher objective response rate of 62.6% compared to 34.4% with chemotherapy. Approximately 85%-90% of HR-positive, HER2-negative cases had actionable HER2 ...